04:34 PM EDT, 08/30/2024 (MT Newswires) -- IO Biotech ( IOBT ) said Friday that an Independent Data Monitoring Committee has recommended the continuation of its late-stage trial of vaccine candidate IO102-IO103 in combination with Merck's ( MRK ) Keytruda as a first-line treatment for patients with unresectable or metastatic melanoma.

No new safety signals were observed at interim analysis, the clinical-stage biopharmaceutical company said. The primary endpoint of progression-free survival is projected to be reached in the first half of 2025.

Price: 1.4400, Change: -0.06, Percent Change: -4.00